Navigation Links
Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015
Date:11/3/2009

3.1.7 Sunrise Medical Breezy® 600

3.1.8 Sunrise Medical Breezy® EC Transport Wheelchair

3.1.9 Sunrise Medical Breezy® EC 2000 Wheelchair -

3.1.10 Sunrise Medical Quickie GTi®

3.1.11 Sunrise Medical Quickie® GT(TM)

3.1.12 Sunrise Medical GT with XTR Suspension

3.1.13 Sunrise Medical Quickie® GP(TM) Swing-Away

3.1.14 Sunrise Medical Quickie® IRIS(TM)

3.2 Drive Medical Transport Chairs Wheelchairs

3.2.1 Gendron MR Transport Wheelchairs

3.2.2 Glide G1 Series - G1 Series SW (Standard Wheelchair )

3.2.3 Glide G1 Series - G1 Series TR (Transit Wheelchair)

3.2.4 Glide G2 Series - G2 Cruz -

3.2.5 Glide G2 Series - G2 Leisure -

3.2.6 Glide G3 Series - G3 Standard -

3.2.7 Graham Field Traveler® SE -

3.2.8 Graham Field Hospital Ward - Ward Wheelchair

3.2.9 Graham Field Transport WheelChair

3.2.10 Glide Special Needs - Comfort Plus 2

3.2.11 Glide Special Needs - Recline Back & Tilt (RBT)

3.2.12 Glide SPX - SPX -

3.3 Highly-Adjustable Modular Wheel Chairs

3.3.1 Sunrise Medical Quickie® TS -

3.3.2 Sunrise Medical Quickie® Recliner

3.3.3 Sunrise Medical Quickie 2 Highly-Adjustable Modular Wheelchair

3.3.4 Sunrise Medical Quickie 2 Highly-Adjustable Modular Wheel Chair

3.3.5 Sunrise Medical Q-Fit(TM) Technology

3.3.6 Sunrise Medical Curb Appeal

3.3.7 Sunrise Medical Quickie® GTX(TM)

3.4 Custom Wheelchairs

3.4.1 Invacare Top End Custom Manual Wheelchairs

3.4.2 Invacare AX3

3.5 Folding Wheel Chairs

3.5.1 Sunrise Medical Quickie® 2 Folding Family

3.5.2 Sunrise Medical Adult Manual Folding Wheelchairs

<
'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... UPI ), a medical device company that develops, ... dysfunctions, today reported financial results for the fiscal 2015 ... for the Company,s Urgent ®  PC Neuromodulation System grew ... as compared to $3.9 million in the third quarter ...
(Date:1/22/2015)... Jan. 22, 2015  Profil Institute for Clinical Research, Inc., ... obesity, announced today a new textbook,  Translational Research Methods ... Springer, a leading global scientific publisher. The ... techniques for use in early phase clinical studies of ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... UCB today announced new ... (certolizumab pegol) was associated with a rapid and sustained ... of moderate to severe rheumatoid arthritis (RA) patients. The ... 2011 Annual Scientific Meeting in Chicago, November 5-9, are ...
... Amgen (NASDAQ: AMGN ) and Pfizer Inc. ... second and final period of the PRESERVE trial.  PRESERVE is ... arthritis (RA) who achieved Disease Activity Score (DAS) 28 low ... plus methotrexate (MTX) in Period one and were randomized to ...
Cached Medicine Technology:New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 2New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 3New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 4New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 5New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 6New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 7New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 8New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 10New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 11Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 2Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 3Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 4Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 5Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 6Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 7Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 8Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 9Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 10Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 11
(Date:1/22/2015)... Deer Path of Huntley -- a ... Happy Hour from 3 p.m. to 4 p.m. on Feb. 13. ... Huntley, Illinois, serves adults with physical disabilities between the ages of ... Day treats, games and sweetheart-themed karaoke. , For more information about ...
(Date:1/22/2015)... January 22, 2015 Woodloch Pines, an ... been selected by TripAdvisor as the number one best large ... best in the world for their annual Travelers’ Choice Awards. ... community . The website is home to millions of unbiased ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... , , ... Democrat in Arcadia, LA recently reported that ... in treating cancers, introducing many new, breakthrough medicines . ... 861 new cancer medicines that are either in late-stage testing, ...
... , , MINNEAPOLIS , Jan. 29 ... it will continue to support efforts to save the General Assistance ... in payments for services, since the existing payments already do not ... to support broad-based tax increases that would support health care programs. ...
... , Statement by Jim Wordelman State Director for AARP Idaho ... of Congress figure out the next steps to take to tackle health ... by the day.  It,s time for Idaho ,s state and federal ... businesses, and retirees to deliver solutions as opposed to more roadblocks to ...
... , LOS ANGELES , Jan. 29 In a ... the nation,s organ donation and transplant community will vote for the best ... Seven Pounds , Return to Me , John Q ... Philadelphia Transplant Movie Night, a group of transplant recipients, living donors and ...
... Bill & Melinda Gates Foundation announced it would dedicate ... vaccine research, development and delivery throughout the developing world. ... pneumonia, diarrhea and malaria take the lives of 5 ... simply because life-saving vaccines don,t reach those who need ...
... Project A.L.S. (New York, NY) and the Robert Packard ... MD) announced that they will partner on, P2 ALS, ... Gehrig,s disease) research exponentially over the next three years. ... leaders in forging productive collaborations among research scientists, will ...
Cached Medicine News:Health News:Cancer Medicines Pipeline Offers Patients Great Hope 2Health News:Doctors Tell Lawmakers to Find a New GAMC Fix 2Health News:Idaho's Health Care Woes Need Solutions, Not More Roadblocks 2Health News:Idaho's Health Care Woes Need Solutions, Not More Roadblocks 3Health News:Nationwide Vote to Determine Best Organ Donation-Themed Movie 2Health News:Project A.L.S. and Packard Center take aim at ALS with $15 million program 2
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... continues the "Consensus Concept" approach to design ... experience of a Scientific Advisory Board. The ... incorporates state-of-the-art features. Consensus Knee implants are ... stability and allow near normal kinematics. The ...
Medicine Products: